Effect of Protein Supplementation on Physical Performance in Older People With Sarcopenia-A Randomized Controlled Trial

Björkman, Mikko P.

2020-02

1

1

Effect of protein supplementation on physical performance in older sarcopenic people– randomized controlled trial

4

Abstract

Objectives: To test the long-term effects of whey-enriched protein supplementation on muscle and physical performance.

Design: A 12-month randomized controlled double blind trial with a 43-month of post-trial follow-up.

Setting: Community dwelling people.

Participants: A total of 218 older (>74 years) people with sarcopenia.

Intervention: 1) control with no supplementation, 2) isocaloric placebo and 3) 20g x 2 whey-enriched protein supplementation. All participants were given instructions on home based exercise, dietary protein and vitamin D supplementation of 20μg/d.

Measurements: Physical performance was assessed by short physical performance battery (SPPB) and continuous summary physical performance scores (CSPPS). Hand grip strength and calf intracellular resistance based skeletal muscle index (CRi-SMI) were measured by bioimpedance spectroscopy (BIS). The measurements were performed at 0, 6, and 12 months. The post-trial follow-up was performed by a postal questionnaire and national census record data.

19   **Results:** The subjects were old (75-96 years) and mostly women (68%). The test supplements had no

20   significant effects on physical performance, the 12-month changes for SPPB being -0.55, -0.05 and

21   0.03 points in control, isocaloric and protein groups (p=0.17), respectively. The changes in CSPPS

22   were similar between the intervention groups (p=0.76). The hand grip strength decreased significantly

23   in all intervention groups and the 12-month changes in CRi-SMI were minor and there were no

24   differences between the intervention groups. Half of the patients (56%) in both supplement groups

25   reported mild gastrointestinal adverse effects. Differences were found neither in the all-cause mortality

26   nor physical functioning in the post-trial follow-up.

27   **Conclusions and implications:** The whey-enriched protein supplementation in combination with low

28   intensity home based physical exercise did not attenuate the deterioration of muscle and physical

29   performance in community dwelling older sarcopenic people.

30

3

Introduction

According to the European Working Group on Sarcopenia in Older People consensus sarcopenia is
defined as low muscle strength, low muscle quantity or quality and low physical performance[1]. Low
muscle strength identifies probable sarcopenia, low muscle quality confirms the diagnosis and if all the
three criteria are met, sarcopenia is considered severe[1]. Age-related muscle loss is closely related to
malnutrition, physical inactivity, inflammation, and cachexia[2,3], which also are hallmarks of frailty[4].
Multifaceted mechanisms underlying age-related muscle loss and weakness range from complex aging
phenomena to life style changes and consequences of clinical diseases. Sarcopenia and frailty are
associated with a risk of adverse outcomes, physical disability, poor quality of life, and increased risk
of morbidity and mortality[1-4].

Many of studies have recently explored to what extent sarcopenia is preventable, and special attention
has been called to physical activity and nutrition[1,5]. The effectiveness of nutritional supplements
containing protein and energy has been gathered into a Cochrane review that consisted of 62
randomized or quasi-randomized controlled trials[5]. Most trials had poor study quality. Supplementation
produced a small but consistent weight gain in older people. Mortality may be reduced in older people
who are undernourished. However, this review found no evidence of improvement in functional benefit
or reduction in the length of hospital stay with supplements. Yanai et al. has reviewed 19 clinical trials
to study effects of protein, amino acids, leucine, vitamin D and beta-hydroxy-beta-methylbutyrate[6]. The
endpoints varied from the muscle synthesis rate and muscle mass indicators to different muscle
functions. Some observational studies suggested a daily dietary protein intake of 1.0-1.2 g/kg for
prevention of sarcopenia. Optimal repartition over each daily meal or 25-30 g of high quality protein

4

per meal was also recommended. However, further studies with larger number of older subjects were warranted.

A comprehensive review summarized the current knowledge about effectiveness of combined exercise and nutrition interventions to improve muscle outcomes in older people[7]. The number of participants (>65 years) ranged from 17 to 217 and the duration of interventions varied from eight weeks to nine months. Enhanced benefits were shown in some trials indicating potential for further larger intervention trials. The oldest people at highest risk were under presented in these trials.

In order to fill this lack of knowledge we enrolled older (>74 years) sarcopenic and community dwelling people to a 12-month double blind randomized controlled trial (RCT) with a 43-month post-trial follow-up. Potential benefits of whey protein have raised special interest[8,9] and prompted us to enrich the test supplement with whey protein. All participants were also given instructions on simple low intensity home based physical exercise and vitamin D supplementation of 20 µg/d[10,11]. We hypothesized that the whey protein supplementation would maintain or improve the physical performance of the participants over the isocaloric placebo and no supplementation.

Methods

General design and interventions

The detailed methods of this 12-month double blind RCT have been published elsewhere[12]. Briefly, a postal screening of the older population (>74 years, n=3275) and further clinical examination of 773 community dwelling older people living in the Porvoo city were performed (appendix figure). The

74 participants had to be able to walk indoors independently although canes and walkers were allowed.

75 They also had low hand grip strength (men ≤30.0 kg, women ≤20.0 kg) or slow habitual gait speed

76 (≤0.80 m/s), low CRi-SMI (2 standard deviations below young adults, 2.06 cm^2/Ω for men and 1.50

77 cm^2/Ω for women) measured by segmental calf BIS (bioimpedance spectroscopy). Other inclusion

78 criteria stated that participants' plasma creatinine was <150 μmol/l, they had no terminal illness

79 (estimated prognosis >6 months), no pacemaker, no bilateral replacement arthroplasty of the knee and

80 finally, and no severe skin lesions in BIS electrode placement sites (dorsal foot, dorsal ankle, lateral

81 knee, dorsal wrist, and dorsal palm.

82 After baseline assessment total of 218 sarcopenic persons were randomly allocated into three arms: 1)

83 control with no supplementation, 3) isocaloric placebo, and 3) 20g x 2 protein supplementation. At

84 baseline, all the participants received written instructions and a short oral counselling on simple low

85 intensity home based physical exercise such as stationary walking and getting up form a chair,

86 importance of dietary protein showing common protein sources without exact target intakes, and the

87 use of vitamin D supplementation with the dose of 20 μg/d. During follow-ups all patients were also

88 orally reminded of these instructions, but the information was not updated. In groups 2 and 3 the

89 participants were instructed to take twice daily a 250 ml beverage as a snack between meals

90 immediately after an exercise session, whereas in group 1 the participants took regular protein-rich

91 foods in a similar fashion. In the protein supplementation group the participants received a maximum

92 of 40 grams (20 grams x 2, 48% whey) of extra milk derived proteins daily compared with 7.5 grams

93 (3.75 grams x 2, 20% whey) in the isocaloric placebo group. After each exercise session and ingestion

94 of supplement the participants recorded the level of exercise and the amount of ingested supplement.

95 The energy content of the test supplements was 70kcal/100ml. The compliance to the home-based

96 exercise, nutritional supplements and vitamin D supplement were assessed by interviewing the patients

97   during each study visit. All supplements were manufactured and provided free of charge by Valio Ltd,

98   Helsinki, Finland. Randomization was performed by computer-generated (Microsoft Excel 2010,

99   Redmont, WA, USA) random list including 100 sets of numbers 1, 2, and 3 to indicate each treatment

100   group. The group treatments were randomized off-site at the start of recruitment and the content of the

101   supplement (isocaloric vs. protein) was kept sealed outside the research group until data collection and

102   analysis of endpoints was complete. All the supplements were packed in blank 250 ml tetras and

103   flavored identically with strawberry.

104   The study was approved by the local Ethics Committee. Informed consent was obtained from each

105   patient or if necessary from their closest proxy (Mini Mental Examination (MMSE) <19 points) before

106   any study procedures which were performed according to good clinical practice. The CONSORT

107   checklist was not available in the preparation of the study protocol, but the results of this randomized

108   controlled trial were reported according to the CONSORT statement within the limits of our data.

109   Recruitment of patients was started during May 2012 and all intervention were completed by the end of

110   year 2014.

111   *Measurements and outcomes*

112   The primary outcome measures included 6- and 12-month changes in physical performance according

113   to the short physical performance battery (SPPB, 0-12)[13] and continuous summary physical

114   performance scores (CSPPS, 0-100), [14,15] and changes in muscle functions (hand grip strength). The

115   questionnaires also included the physical component of the RAND-36 scale[16]. Two consecutive

116   measures of handgrip strength (kg) from both hands were measured to the nearest 1.0 kg with subjects

117   sitting in an upward position and the arm in a 90-degree angle (JAMAR dynamometer, Saehan Corp.

118   Masan, Korea)[17]. The mean of the best result from both hands was recorded. Habitual gait speed was

measured over a 4-meter course without a walking aid when possible and the best time of two attempts

was recorded to calculate the gait speed = distance (m)/time (s)[18]. The patients were instructed to walk

down a hallway through a 1-meter zone for acceleration, a central 4- meter "testing" zone, and a 1-

meter zone for deceleration. Chairs used for the SPPB chair stand test had a back rest without arm rests,

with a sitting height of 42-44cm and a sitting depth of 42-45cm. Same chairs were used during follow-

up measurements. Height and weight were measured, and body mass index calculated accordingly.

Skeletal muscle indices (SMI) were measured with a single channel, tetra polar BIS device (SFB7,

ImpediMed Ltd., Eight Miles Plains, Queensland, Australia) that scans 256 frequencies between 4 kHz

and 1000 kHz. Raw data were analyzed with the supporting software (version 5.3.1.1, SFB7,

ImpediMed Ltd., Eight Miles Plains, Queensland, Australia) supplied by the manufacture to obtain

values for calculation of CRi-SMI = electrode distance^2/calf intracellular resistance[19,20]. Single

frequency (50 kHz) resistance data were obtained and Janssen equation used to calculate the skeletal

muscle mass in order to determine the single frequency skeletal muscle mass index (SF-SMI) = skeletal

muscle mass/height^2. The measurements were performed according to the instructions of the

manufacturer and under standardized conditions (at the same time of day, empty bladder etc,).

Nutritional status was assessed by the Mini Nutritional Assessment (MNA)[21] and a three-day dietary

record[22,]. Cognition was assessed by the MMSE[23]. All measurements were performed at baseline, at 6,

and 12 months.

Post-trial follow-up

The census status of the participants in the Porvoo Trial was obtained from the bureau of Official

Statistics of Finland (SVT) in April 2016. Thereafter a postal questionnaire was sent to the survivors.

The questionnaire contained questions about housing, need for help, functioning, and activities of daily

living as well as the physical component of RAND-36 scale.

142 *Statistics*

143 Sample size calculation has been presented in our previous article.[12] Statistical comparison between the

144 groups at baseline was performed using analysis of variance or the chi-square test when appropriate.

145 All participants assessed at baseline, 6-month, and 12-month examinations were included in the data

146 analyses of changes in SPPB and CSPPS (modified intention to treat). Repeated measures were

147 analyzed using generalized estimating equation (GEE) models with the unstructured correlation

148 structure. GEEs were developed as an extension of the general linear model (e.g., ordinary least squares

149 regression analysis) to analyze longitudinal and other correlated data. GEE models take into account

150 the correlation between repeated measurements in the same subject; models do not require complete

151 data and can be fitted even when individuals do not have observations at all time-points. The 95%

152 confidence intervals (CIs) and statistical models were obtained using bootstrapping in cases of

153 violation of assumptions. Stata version 13.1 (Stata Corp., LP, College Station, TX) was used for the

154 analyses.

155

156 **Results**

157

158 The subjects were old (75-96 years) and women (68%) outnumbered men (Table 1). The baseline

159 MMSE scores ranged from 15 to 30 the mean score being 26 and the mean number of daily prescribed

160 drugs was 5.7. The baseline characteristics of subjects did not differ after randomization (Table 1). A

161 total of 40 (18%) subjects (22 controls, 8 in protein group, 10 isocaloric group, p=0.005) dropped out

162 during the intervention period, the majority of them (n= 23) within the first six months (Supplemental

163 figure S1). The drop-outs in the control group were more frequent in men (57% vs. 20%, p=0.002),

164 they had lower MMSE (24.8 vs 26.3, p=0.027) and lower MNA (21.3±2.8 vs 23.2±2.7, p=0.010) at

165 baseline than those who completed the study. According to the dietary records there were no

166 differences among the three groups in the compliance to the nutritional supplement or in the physical

167 activity. The mean daily dietary protein intake (supplements excluded) ranged from 0.97 g/kg to 1.15

168 g/kg in the three groups at six- and 12-month examinations and no significant changes or differences

169 between the groups were observed during follow-up (data not shown). Subjects reported taking on

170 average 58% of the daily supplement volume in the protein group, the respective figure being 64% in

171 the isocaloric group. The mean time spent in different physical activities (house hold work, home

172 exercise, walking, etc.) was estimated at 4.0, 3.5 and 3.9 h/week (p = 0.66) in the control, protein and

173 isocaloric groups, respectively. One in two (n=98, 45 %) of the subjects was estimated to have a good

174 compliance (≥50% of the supplement and ≥2h/week of physical activity) throughout the 12-month

175 intervention.

176 The two test supplements had no significant effects on indicators of physical performance. Thus, the

177 changes the short physical performance battery (SPPB) and continuous summary physical performance

178 scores (CSPPS) did not differ between the groups during the 12-month intervention period (Figure 1).

179 The same held true for the physical component of RAND-36 scores (data not shown). On the contrary,

180 physical performance tended to deteriorate during the trial period, the mean (95%CIs) 12-month

181 changes for SPPB being -0.55 (-1.02, -0.07), -0.05 (-0.47, 0.38) and 0.03 (-0.39, 0.46) points in the

182 control, isocaloric and protein groups, respectively. The respective CSPPS values were -1.9 (-4.4,

183 0.62), -1.1 (-3.4, 1.2) and -2.3 (-4.5, -0.01).

184 There was a slight but significant weight gain during the first six months in both supplement groups

185 that leveled off at 12-months, but again no significant differences were found between the three

186 intervention groups (Figure 2). The hand grip strength decreased significantly and similarly in all three

187 groups (Figure 2). The mean (95%CIis) 12-month changes were -1.9 kg (-2.7, 1.1), -1.7 kg (-2.5, -0.99)

188 and -1.9 kg (-2.6, -1.1) in the control, isocaloric and protein groups, respectively. The muscle mass

189 estimated by means of CRi-SMI decreased slightly in both supplemented groups, but no statistically

190 significant differences were observed among the three groups (Figure 3A). The mean (95%Cis) 12-

191 month changes in CRi-SMI were -0.01 (-0.05, 0.04), -0.05 (-0.09, -0.01) and -0.05 (-0.10, -0.01) in

192 control, isocaloric and protein groups, respectively. The second muscle index, SF-SMI remained

193 practically unchanged (Figure 3B). Secondary analyses showed that differences of the changes in SPPB

194 and CSPPS were insignificant also in those with good compliance (data not shown).

195 The test supplements caused a significant increase in gastrointestinal complaints. Up to 56% in both

196 test groups reported some adverse effects, whilst the respective figure was 9 % in the control group.

197 The taste of supplements caused concern in some cases (n=13), but the gastrointestinal symptoms

198 included also feelings of early satiety, nausea, diarrhea and constipation similarly in both supplement

199 groups. The complaints in the control group were limited to the required documentation of dietary

200 records and physical activity.

201 Of the 218 participants 46 died within the 43-month follow-up. No differences were found in the all-

202 cause mortality among the test groups (Table 2). A total of 137 survivors responded to the post-trial

203 follow-up postal questionnaire. The majority was still living at home without help and no differences

204 were found in the physical component of RAND-36 scores among the intervention groups.

Discussion

Our study showed that the whey enriched protein supplementation in combination with low intensity home based physical exercise did not attenuate the deterioration of muscle and physical performance in community dwelling older sarcopenic people, but caused a temporary weight gain and lead to mild gastrointestinal complaints in half of the participants. The results of the present study do not rule out possible positive effects of protein supplementation in some groups, but strongly suggests that its impact is not decisive in real life home-dwelling older people who already have significant manifestations of muscle loss and weakness.

The results are in accordance with numerous smaller studies on various target groups[5-7]. They are also in line with the results of our trial on nursing home residents, in which the six-month supplementation with whey protein fractions resulted in an increase in body weight, tended to increase whole body fat free mass but did not improve functioning[24].

Plausible explanations for the lacking effectiveness is the relatively good nutritional status and adequate protein intake of these sarcopenic subjects. In fact, the baseline energy intake was within the ranges of recommendations and the BMI of participants was not low. Furthermore, the baseline daily protein intake was 1.0 g/kg, and in line with the recommendations, although the optimum amount of dietary protein has been debated intensively[5,6,25]. Despite the fact that protein depletion is a significant risk for the development of sarcopenia in epidemiologic studies, several studies have failed to demonstrate positive effects of excess protein intake on muscle mass and physical performance[5,6,7,9]. That holds true for different protein extractions including whey protein fractions and essential amino acids[5,6,7].

227 Recent reviews and meta-analyses published after termination of our trial illustrate that the protein
228 supplementation hardly solves the sarcopenia problem of older adults. The meta-analysis of Tieland et
229 al. suggested that according to eight studies protein or amino acid supplementations had no positive
230 effects on lean body mass or muscle strength in predominantly healthy elderly people[26]. Hou et al.
231 summarized the results of 21 trials and found that the protein supplementation combined with
232 resistance training effective in the enhancing muscle mass and strength but did not improve other
233 muscle functions[27]. On the contrary, Ten Haaf et al. included 36 studies in their meta-analysis and
234 concluded that that the protein supplementation does not lead to increases in lean body mass, muscle
235 strength or physical performance in non-frail community older adults[28]. They recommend further
236 studies to clarify, whether specific protein supplementations are beneficial for older people with low
237 habitual protein intake. Of the newest trials that of Bo et al. is closest to ours[29]. They found that in a 6-
238 month study of 60 sarcopenic older patients that the combined supplementation of whey protein.
239 vitamin D and E improved muscle mass and strength as well as anabolic markers in older adults with
240 sarcopenia.

241 Of the life-style factors physical activity and muscle training have been proved to be the most
242 important in the prevention and restoration of muscle loss in all age groups[7]. The importance of
243 progressive resistance exercise in improving physical performance has been particularly emphasized,
244 during which the nutritional requirements may also be increased. In order to avoid deteriorating effects
245 of the sedentary life style, all participants were advised to physical activity, importance of dietary
246 protein and to use vitamin D according to recommendations. It is likely that the level of physical
247 activity was not high enough to prevent the decline in muscle functions. In this respect, this study
248 conveys an important message: physical activation of older home-dwelling sarcopenic people is not an
249 easy task.

250   The negative result of the present study should be viewed in light of the fact that this trial is one of the

251   largest and the most long-lasting RCT published on this area. It was also complemented by a long-term

252   post-trial follow-up. The focus of study and the real-life approach to the problem are other indisputable

253   strengths. The exclusion criteria were kept as few as possible. It is worth noting that the participants

254   were older than in most previous studies and therefore at the highest risk of both deteriorating

255   sarcopenia and its multiple consequences. The use of bioimpedance spectroscopy (BIS) to measure

256   changes in muscle has enabled us to include geriatric patients requiring home visits for the

257   examinations.

258   Some weaknesses are difficult to be avoided in real life experiments. The drop-out rate, 18% within

259   one year, may be tolerable in the older population. Interestingly, the drop-outs were most common in

260   the control group conceivably due to the lower incentives and motivation compared with participants

261   receiving nutritional supplements free of charge. The fact that the drop-outs also had lower MMSE and

262   lower MNA at baseline may have also falsely improved the observed results in the control group

263   possibly masking the age-related decrease in the skeletal muscle index (Figure 3).

264   The relatively low compliance and adherence to the test supplements is a certain cause for concern

265   because it could dilute possible positive effects of supplements. However, even with the average of

266   58% ingested volume the protein supplementation dose was 23.2 g/d, which is comparable to most

267   previous studies[5,6,7]. Furthermore, the significant differences in adverse effects indicate active use of

268   the test supplements and obstacles for the wide-scale usage of long term nutritional supplementation in

269   prevention of sarcopenia in older populations.

270   Despite conflicting clinical trial results the theoretical knowledge has kept continuous interest in the

271   role of whey protein supplementation in the prevention and even treatment of sarcopenia. A recent

272   RCT PROVIDE showed improvements in muscle mass and lower-extremity function among

273 sarcopenic older adults with a 13-week vitamin D and leucine-enriched whey protein oral nutritional

274 supplementation[30]. A post-hoc analysis of the trial also suggested that sufficient baseline levels of 25-

275 hydroxyvitamin D and protein intake may be required to increase muscle mass as a result of

276 intervention with a vitamin D and protein supplement in sarcopenic older adults[31]. A 12-week RCT on

277 supplementation with whey protein, essential amino acids, and vitamin D, in conjunction with age-

278 appropriate exercise boosted fat-free mass and strength and contributed to well-being in sarcopenic

279 elderly[32]. In addition, a new trials have been registered, in which the effects of light training and

280 nutrients including whey protein will be tested in older people on wide array of variables[33,34].

281 Furthermore, on-going PROMISS trial investigates inclusion of protein rich foods alone or with advice

282 to use them in conjunction with normal daily physical activity on physical performance in community-

283 dwelling older adults[35].

284 ***Conclusion and implications***

285 in this study the whey enriched protein supplementation in combination with low intensity home based

286 physical exercise did not attenuate the deterioration of muscle and physical performance in community

287 dwelling older sarcopenic people, but caused a temporary weight gain and led to mild gastrointestinal

288 complaints in more than half of the participants.

References

1. Cruz-Jentoft AJ, Bahat G, Bauer J et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.

2. Rolland Y, Czerwinski S, Abellan Van Kan G et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12:433-450.

3. Evans CJ, Chiou CF, Fitzgerald KA et al. Development of a new patient-reported outcome measure in sarcopenia. J Am Med Dir Assoc 2011;12:226–233.

4. Fried LP, Tangen CM, Walston J et al. Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–M156.

5. Milne AC, Potter J, Vivanti A et al. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2009;2:CD003288.

6. Yanai H. Nutrition for sarcopenia. J Clin Med Res 2015;7:926-931.

7. Denison HJ, Cooper C, Sayer AA et al. Prevention and optimal management of sarcopenia: a review of combined exercise and nutrition interventions to improve muscle outcome in older people. Clinical Interventions in Aging 2015;10:859-867.

8. Katsanos CS, Chinkes DL, Paddon-Jones D et al. Whey protein ingestion in elderly persons results in greater muscle protein accrual than ingestion of its constituent essential amino acid content. Nutr Res 2008;28:651–658.

311   9. Hulmi JJ, Lockwood CM, Stout JR. Effect of protein/essential amino acids and resistance

312   training on skeletal muscle hypertrophy: A case for whey protein. Nutr Metab (Lond)

313   2010;7:51.

314   10. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al. Fall prevention with supplemental

315   and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ

316   2009;339:b3692.

317   11. Zhu K, Austin N, Devine A et al. A randomized controlled trial of the effects of vitamin D on

318   muscle strength and mobility in older women with vitamin D insufficiency. J Am Geriatr Soc

319   2010;58:2063-2068.

320   12. Bjorkman M, Suominen MH, Pitkala KH et al. Porvoo sarcopenia and nutrition trial: effects of

321   protein supplementation on functional performance in sarcopenic older people -study protocol

322   for a randomized controlled trial. Trials 2013;14:397-404.

323   13. Guralnik JM, Simonsick EM, Ferrucci L et al. A short physical performance battery assessing

324   lower extremity function: association with self-reported disability and prediction of mortality

325   and nursing home admission. J Gerontol 1994;49:M85–M94.

326   14. Nieves JW, Zion M, Pahor M et al. Evaluation of continuous summary physical performance

327   scores (CSPPS) in an elderly cohort. Aging Clin Exp Res 2005;17:193-200.

328   15. Nieves JW, Li T, Zion M et al.The clinically meaningful change in physical performance

329   scores in an elderly cohort. Aging Clin Exp Res 2007; 19:484–491.

330   16. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ

331   1993; 2:217-227.

332   17. Bohannon RW: Hand-grip dynamometry predicts future outcomes in aging adults. J Geriatr

333   Phys Ther 2008;31:3-10.

334 18. Working Group on Functional Outcome Measures for Clinical Trials: Functional outcomes for

335 clinical trials in frail older persons: time to be moving. J Gerontol A Biol Sci Med Sci

336 2008;63:160-164.

337 19. Björkman MP, Finne-Soveri H, Pilvi TK et al. Bioimpedance spectroscopy as a measure of

338 physical functioning in nursing home residents. Aging Clin Exp Res 2012; 24:612-618.

339 20. Yamada Y, Schoeller DA, Nakamura E et al. Extracellular water may mask actual muscle

340 atrophy during aging. J Gerontol A Biol Sci Med Sci 2010; 65:510-516.

341 21. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition the mini

342 nutritional assessment. Clin Geriatr Med. 2002;18:737-757.

343 22. Suominen MH, Kivisto SM, Pitkala KH. The effects of nutrition education on professionals'

344 practice and on the nutrition of aged residents in dementia wards. Eur J Clin Nutr 2007;

345 61:1226-1232.

346 23. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading

347 the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198.

348 24. Björkman MP, Finne-Soveri H, Tilvis RS. Whey protein supplementation in nursing home

349 residents, A randomized controlled trial. Eur Ger Medi 2012; 3:161-166.

350 25. Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of

351 sarcopenia. Curr Opin Clin Nutr Metab Care 2009;12:86-90.

352 26. Tieland M, Franssen R, Dullemeijer C et al. The Impact of Dietary Protein or Amino Acid

353 Supplementation on Muscle Mass and Strength in Elderly People: Individual Participant Data

354 and Meta-Analysis of RCT's. J Nutr Health Aging 2017;21(9):994-1001. doi: 10.1007/s12603-

355 017-0896-1.

Kentän koodi muuttunut

Kentän koodi muuttunut

356 27. Hou L, Lei Y, Huo C et al. Effect of Protein Supplementation Combined with Resistance

357   Training on Muscle Mass, Strength and Function in the Elderly: A Systematic Review and

358   Meta-Analysis. J Nutr Health Aging. 2019;23(5):451-458. doi: 10.1007/s12603-019-1181-2.

359 28. Ten Haaf DSM, Nuijten MAH, Maessen MFH et al. Effects of protein supplementation on lean

360   body mass, muscle strength, and physical performance in nonfrail community-dwelling older

361   adults: a systematic review and meta-analysis. Am J Clin Nutr. 2018 Nov 1;108(5):1043-1059.

362   doi: 10.1093/ajcn/nqy192.

363 29. Bo Y, Liu C, Ji Z et al. A high whey protein, vitamin D and E supplement preserves muscle

364   mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized

365   controlled trial. Clin Nutr. 2019 Feb;38(1):159-164. doi: 10.1016/j.clnu.2017.12.020. Epub

366   2018 Jan 9.

367 30. Bauer JM, Verlaan S, Bautmans I et al. Effects of a vitamin D and leucine-enriched whey

368   protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study:

369   a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 2015;16:740-747.

370 31. Verlaan S, Maier AB, Bauer JM et al. Sufficient levels of 25-hydroxyvitamin D and protein

371   intake required to increase muscle mass in sarcopenic older adults - The PROVIDE study. Clin

372   Nutr 2017;17. pii: S0261-5614:30010-9.

373 32. Rondanelli M, Klersy C, Terracol G et al. Whey protein, amino acids, and vitamin D

374   supplementation with physical activity increases fat-free mass and strength, functionality, and

375   quality of life and decreases inflammation in sarcopenic elderly. Am J Clin Nutr 2016;103:830-

376   40.

377 33. Bechshøft RL, Reitelseder S, Højfeldt G et al. Counteracting age-related loss of skeletal muscle

378   mass: a clinical and ethnological trial on the role of protein supplementation and training load

379   (CALM Intervention Study): Study protocol for a randomized controlled trial. Trials

380   2016;17:397.

381 34. Kirn DR, Koochek A, Reid KF et al. The Vitality, Independence, and Vigor in the Elderly 2

382   Study (VIVE2): Design and methods. Contemp Clin Trials 2015;43:164-71.

383 35. www.promiss-vu.eu Accessed on Jan 15, 2019.

384 **Figure legends**

385

386 Figure 1. Changes in short physical performance battery (SPPB) and continuous summary physical

387 performance scores (CSPPS) by the intervention group. N=218, p-values and estimates calculated by

388 generalized estimating equation models with the unstructured correlation structure, p-values < 0.050

389 are considered statistically significant.

390

391 Figure 2. Changes in body weight and hand grip strength by the intervention group. N=218, p-values

392 and estimates calculated by generalized estimating equation models with the unstructured correlation

393 structure, p-values < 0.050 were considered statistically significant.

394

395 Figure 3. Changes in calf intracellular resistance skeletal muscle index (Cri-SMI) and single frequency

396 skeletal muscle index (SF-SMI) by the intervention group. N=218, p-values and estimates calculated by

397 generalized estimating equation models with the unstructured correlation structure, p-values < 0.050

398 were considered statistically significant.

399

Table 1. Characteristics of participants

Variable	Control	Isocaloric	Protein	P-value
Number	72	73	73	
Age, years	83.7±5.1	84.0±3.9	83.6±4.7	.881
Women, %	70.8	62.5	69.9	.504
Number of Daily Drugs	5.7±3.1	5.3±2.7	6.1±2.8	.281
Mini Mental State Examination	25.8±2.5	25.6±3.5	26.2±2.7	.420
SF-SMI[a], kg/m^2	7.6±1.7	7.7±1.7	7.3±1.6	.356
CRi-SMI[b], cm^2/Ω	1.29±0.34	1.27±0.35	1.28±0.34	.959
Short Physical Performance Battery	7.9±2.8	7.7±2.7	7.8±3.0	.940
Gait Speed, m/s	0.85±0.31	0.84±0.28	0.88±0.34	.748
Hand Grip Strength, kg	19.4±5.9	20.5±6.7	18.5±6.5	.171
Mini Nutritional Assessment	22.7±2.8	22.9±2.6	22.3±3.0	.445
Body Mass Index	26.3±3.8	26.8±4.0	25.3±4.0	.064
Energy intake, kcal/d	1644±419	1698±469	1641±517	.770
Protein intake, g/kg/d	1.0±0.3	1.0±0.4	1.1±0.5	.720

Comparison performed using analysis of variance or the chi-square test when appropriate.

[a]Single Frequency Skeletal Muscle Index

[b]Calf Intracellular Resistance Skeletal Muscle Index

400

Table 2. Physical functioning and need for help at four-year follow-up

Variable	Control	Isocaloric	Protein	P-value
	N = 45	N = 46	N = 46	
At home, %	97.8	97.8	95.6	.803
At home, without help, %	56.5	66.7	68.9	.714
Physical RAND-36 (SD)	39.9 (32.1)	45.2 (25.1)	43.8 (28.8)	.393
No difficulties outdoors, %	42.2	41.3	45.6	.915
No difficulties indoors, %	57.8	68.4	67.4	.545

401　Comparison performed using chi-square test.

Appendix Figure. Flowchart of participants